OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
Unique leukemia R&D partnering opportunities
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Ahead of EHA 2026, OPALE highlights the leukemia signals pharma and biotech teams should already be watching
04/06/2026
Ahead of EHA 2026, OPALE highlights the leukemia research signals pharma and biotech teams should watch, from MRD and resistance to cell therapies and translational strategy.
> Read moreOn May 20, International Clinical Trials Day highlights a key challenge in leukemia: turning biology into clinical proof
20/05/2026
On International Clinical Trials Day, OPALE highlights the central role of clinical trials in leukemia, from biomarker strategy to patient stratification and clinical proof.
> Read moreOPALE à la SFH 2026 : faire converger recherche, clinique et industrie en leucémie
27/03/2026
À la SFH 2026, OPALE met en avant son offre de recherche partenariale, LEUKEMIA 360, OncoPlanning et ses opportunités de collaboration en leucémie.
> Read more